Recent advances in improving the management of sickle cell disease

Blood Reviews

Volumn 23, Issue SUPPL. 1, 2009, Pages

  Inati, Adlette ^a  

^a RAFIC HARIRI UNIVERSITY HOSPITAL   (Lebanon)

Author keywords

Deferasirox; Iron chelation therapy; Iron overload; Sickle cell disease; Stroke

Indexed keywords

DEFERASIROX; DEFEROXAMINE;

BETA THALASSEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXCHANGE BLOOD TRANSFUSION; FERRITIN BLOOD LEVEL; HUMAN; IRON BALANCE; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; PATIENT COMPLIANCE; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; HEALTH PLANNING GUIDELINES; HUMANS; IRON CHELATING AGENTS; TREATMENT OUTCOME;

EID: 73349137948     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(09)70004-9     Document Type: Review

References (28)

1. Inati A., Koussa S., Taher A., et al. Sickle cell disease: new insights into pathophysiology and treatment. Pediatr Ann 37 (2008) 311-325
2. Castro O., Brambilla D.J., Thorington B., et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 84 (1994) 643-649
3. Gill F.M., Sleeper L.A., Weiner S.J., et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease. Blood 86 (1995) 776-783
4. Ohene-Frempong K., Weiner S.J., Sleeper L.A., et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 91 (1998) 288-294
5. Gaston M.H., Verter J.I., Woods G., et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 314 (1986) 1593-1599
6. Vichinsky E., Hurst D., Earles A., et al. Newborn screening for sickle cell disease: effect on mortality. Pediatrics 81 (1988) 749-755
7. Vichinsky E.P. Comprehensive care in sickle cell disease: its impact on morbidity and mortality. Semin Hematol 28 (1991) 220-226
8. Adams R.J., McKie V.C., Hsu L., et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med 339 (1998) 5-11
9. Vichinsky E.P., Haberkern C.M., Neumayr L., et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med 333 (1995) 206-213
10. Ohene-Frempong K. Indications for red cell transfusion in sickle cell disease. Semin Hematol 38 1 Suppl 1 (2001) 5-13
11. Pegelow C.H., Adams R.J., McKie V., et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr 126 (1995) 896-899
12. Adams R.J., and Brambilla D. Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators. Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. N Engl J Med 353 (2005) 2769-2778
13. Al-Refaie F.N., Wickens D.G., Wonke B., et al. Serum non-transferrin bound iron in beta-thalassaemia major patients treated with desferrioxamine and L1. Br J Haematol 82 (1992) 431-436
14. Darbari D.S., Kple-Faget P., Kwagyan J., et al. Circumstances of death in adult sickle cell disease patients. Am J Haematol 81 (2006) 858-863
15. Aduloju S.O., Palmer S., and Eckman J.R. Mortality in sickle cell patient transitioning from pediatric to adult program: 10 years grady comprehensive sickle cell center experience. Blood 112 (2008) abstract 1426.
16. Fung E.B., Harmatz P.R., Milet M., et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion 48 (2008) 1971-1980
17. Cappellini M.D., Porter J., El-Beshlawy A., et al. Tailoring iron chelation by iron intake and serum ferritin: prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica (2009) [Epub ahead of print].
18. Breuer W., Hershko C., and Cabantchik Z.I. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus Sci 23 (2000) 185-192
19. Inati A., Taha M., Musallam K.M., et al. Magnetic resonance imaging R2 mapping accurately estimates iron overload in sickle cell disease patients. EHA (2009) abstract 1285.
20. Inati A, Musallam KM, Wood JC, et al. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease. Blood; in press.
21. Inati A., Musallam K.M., Wood J.C., et al. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease. Eur J Haematol 83 (2009) 565-571
22. Inati A., Musallam K.M., Taha M., et al. Magnetic resonance imaging T2* in the evaluation of cardiac iron overload in patients with sickle cell disease. EHA (2009) abstract 1286.
23. Sickle Cell Society, UK, 2008. Available at: www.sicklecellsociety.org/CareBook.pdf
24. National Institutes of Health, National Heart, Lung, and Blood Institute, and and Division of Blood Diseases and Resources. The management of sickle cell disease (NIH Publication No 02-2117) (2002), NIH, Bethesda, MD
25. Vichinsky E., Onyekwere O., Porter J., et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 136 (2007) 501-508
26. Vichinsky E., Pakbaz Z., Onyekwere O., et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematol 119 (2008) 133-141
27. Vichinsky E. Coates T, Thompson AA, et al. Deferasirox (Exjade®), the once-daily oral iron chelator, demonstrates safety and efficacy in patient with sickle cell disease (CD: 3.5-year follow-up. ASH 2008: abstract 1420.
28. Raphael J.L., Bernhardt M.B., Mahoney D.H., et al. Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatr Blood Cancer 52 (2009) 616-620